Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma

This publication has 27 references indexed in Scilit:

• Trends in Omalizumab Utilization for Asthma: Evidence of Suboptimal Patient Selection
  The Journal of Allergy and Clinical Immunology: In Practice, 2018
• Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
  New England Journal of Medicine, 2018
• Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations
  PharmacoEconomics, 2018
• Nonadherence in the era of severe asthma biologics and thermoplasty
  European Respiratory Journal, 2018
• Asthma Cost-Effectiveness Analyses: Are We Using the Recommended Outcomes in Estimating Value?
  The Journal of Allergy and Clinical Immunology: In Practice, 2018
• A randomised clinical trial of feedback on inhaler adherence and technique in patients with severe uncontrolled asthma
  European Respiratory Journal, 2018
• Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study
  Journal of Asthma, 2017
• Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
  The Lancet, 2016
• Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
  The Lancet Respiratory Medicine, 2015
• Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
  The Lancet, 2012